2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 130 filers reported holding 2SEVENTY BIO INC in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,309,971 | -58.6% | 4,415,809 | +6.8% | 0.00% | -100.0% |
Q2 2023 | $41,848,061 | +29.8% | 4,135,184 | +30.8% | 0.00% | 0.0% |
Q1 2023 | $32,237,333 | +14.4% | 3,160,523 | +5.1% | 0.00% | 0.0% |
Q4 2022 | $28,171,955 | -25.0% | 3,006,612 | +16.4% | 0.00% | 0.0% |
Q3 2022 | $37,570,000 | +12.5% | 2,582,136 | +2.1% | 0.00% | 0.0% |
Q2 2022 | $33,383,000 | +22.8% | 2,528,936 | +58.7% | 0.00% | 0.0% |
Q1 2022 | $27,189,000 | -33.8% | 1,593,764 | -0.6% | 0.00% | 0.0% |
Q4 2021 | $41,076,000 | – | 1,602,683 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 4,890,706 | $49,493,945 | 6.81% |
CHI Advisors LLC | 852,007 | $8,622,311 | 2.62% |
Casdin Capital, LLC | 2,023,913 | $20,482,000 | 1.79% |
Newtyn Management, LLC | 737,744 | $7,465,969 | 1.76% |
Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,258,078 | 1.47% |
DAFNA Capital Management LLC | 496,416 | $5,023,730 | 1.37% |
AlphaCentric Advisors LLC | 180,000 | $1,821,600 | 1.01% |
SECTORAL ASSET MANAGEMENT INC | 462,485 | $4,680,348 | 0.78% |
CLOUGH CAPITAL PARTNERS L P | 529,110 | $5,354,593 | 0.54% |
Bleichroeder LP | 255,230 | $2,582,928 | 0.52% |